1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ImpediMed Limited

ImpediMed Limited

IPDQF
ImpediMed LimitedUS flagOther OTC
0.01
USD
- -
- -
11.52MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
0.01
Basic EPS, GAAP
-0.04
-0.04
-0.05
-0.08
-0.07
-0.07
-0.06
-0.04
-0.02
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
-0.04
-0.03
-0.04
-0.07
-0.07
- -
-0.01
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
0.04
0.08
0.21
0.11
0.04
-0.02
- -
- -
0.01
0.01
- -
-0.01
Tangible Book Value per Share
0.04
0.05
0.12
0.25
0.14
0.08
0.03
0.04
0.02
0.02
0.03
0.01
- -
Basic Weighted Avg Shares
195
211
281
335
393
395
397
595
1,202
1,679
1,800
2,022
2,019
Sales/Revenue/Turnover
3
4
5
6
6
5
4
6
8
10
11
10
13
Operating Margin (%)
-347.75
-227.26
-312.65
-452.06
-533.33
-638.71
-659.15
-448.84
-276.22
-205.21
-204.4
-241.76
-190.44
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
2
3
2
2
5
Net Income, GAAP
-8
-8
-15
-26
-28
-27
-24
-21
-21
-20
-21
-20
-23
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-309.7
-225.36
-305.47
-448.63
-478.17
-566.48
-588.65
-375.43
-247.89
-189.37
-182.43
-196.86
-182.62
Working Capital
8
11
32
82
56
32
10
20
18
39
46
25
22
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
1
1
14
Total Equity
11
14
35
85
59
36
16
27
26
51
61
41
20
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-90.1
-123.2
-94.26
-55.97
-49.49
-94.32
- -
- -
- -
- -
-98.09
-131.41
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.19%
5.96%
-49.69%
Free Cash Flow
13.21%
5.03%
-68.15%
Net Income, GAAP
6.76%
1.99%
17.42%
Sales/Revenue/Turnover
12.21%
19.09%
26.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
11
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
13

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Erik Anderson
Full Time Employees
77
Sector
Healthcare
Industry
Medical - Devices
Address
50 Parker Court Pinkenba QLD Australia 4008
IPO Date
Sep 25, 2012
Website
impedimed.com
Similar Companies
Avisa Diagnostics Inc. (AVBT.CN)
Mauna Kea Technologies S.A. (MKEAF)
Drägerwerk AG & Co. KGaA (DGWPF)
ReWalk Robotics Ltd. (RWLK)
Aquarius Surgical Technologies Inc. (AQQRF)
Implanet S.A. (ALIMP.PA)
Business
ImpediMed Limited operates as a leading medical technology innovator, specializing in the development, production, and global distribution of bioimpedance spectroscopy (BIS) devices and sophisticated software platforms. The company's core product, the SOZO Digital Health Platform, delivers non-invasive measurements for managing critical health conditions. This includes the early detection and clinical assessment of lymphedema, especially breast cancer-related lymphedema, for which its technology is exclusively cleared by the FDA. SOZO also offers comprehensive fluid status monitoring for heart failure patients and detailed body composition analysis. Recently, ImpediMed introduced SOZO Pro, tailored for individuals with cardiac implantable devices. The company primarily leverages a Software as a Service (SaaS) subscription model, providing its advanced diagnostic solutions to hospitals, clinics, and cancer treatment centers across Australia, Europe, and North America. Founded in 1999, ImpediMed Limited is headquartered in Pinkenba, Australia.

Company News

APIChatGPT

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Shareholder/Analyst Call Prepared Remarks Transcript

  • seekingalpha.com

    ImpediMed Limited (IPDQF) Q2 2026 Earnings Call Transcript